Rankings / Muscle & Strength
Muscle & Strength
TRT, SARMs, anabolic steroids, peptide GH-secretagogues, and the off-label performance corner. Large effect sizes, meaningful risk, and serious legal exposure.
| # | Compound | Ev | Bn | Sf | Grade · Score |
|---|---|---|---|---|---|
| 1 | Resistance training Movement | 10 | 8 | 9 | S 9.3 |
| 2 | Beta-alanine Carnosine precursor | 8 | 6.5 | 9 | A+ 8.2 |
| 3 | Blood flow restriction (BFR) training Movement | 8 | 8 | 7 | A- 7.6 |
| 4 | Testosterone (TRT / supraphysiological) Endogenous androgen (AR agonist) | 8 | 8 | 5 | B 6.8 |
| 5 | Anavar (oxandrolone) Oral anabolic steroid | 8 | 6.5 | 5 | B 6.6 |
| 6 | Sodium bicarbonate Extracellular buffer | 8 | 6.5 | 5 | B 6.6 |
| 7 | Tesamorelin Stabilized GHRH analog | 8 | 5 | 3.5 | B- High-risk profile 5.8 |
| 8 | Deca-Durabolin (nandrolone decanoate) Injectable 19-nor steroid | 8 | 8 | 2 | C+ High-risk profile 5.6 |
| 9 | Dianabol (methandrostenolone / methandienone) Oral anabolic steroid (C17-aa) | 8 | 8 | 2 | C+ High-risk profile 5.6 |
| 10 | EPO / erythropoiesis-stimulating agents (ESAs) Erythropoietin receptor agonist | 8 | 8 | 2 | C+ High-risk profile 5.6 |
| 11 | Nandrolone (phenylpropionate / other esters) Injectable 19-nor steroid | 8 | 8 | 2 | C+ High-risk profile 5.6 |
| 12 | Other WADA-listed anabolic androgenic steroids (AAS long tail) Anabolic androgenic steroids / prohormones | 8 | 8 | 2 | C+ High-risk profile 5.6 |
| 13 | Sermorelin GHRH(1-29) analog | 4.5 | 5 | 7 | C+ 5.6 |
| 14 | Ostarine (MK-2866 / enobosarm) SARM | 6 | 5 | 5 | C+ 5.5 |
| 15 | Primobolan (methenolone) Injectable/oral anabolic | 6 | 5 | 5 | C+ 5.5 |
| 16 | Winstrol (stanozolol) Oral/injectable anabolic steroid | 8 | 6.5 | 2 | C+ High-risk profile 5.4 |
| 17 | Boldenone (Equipoise) Injectable veterinary anabolic | 6 | 8 | 3.5 | C+ High-risk profile 5.3 |
| 18 | Anadrol (oxymetholone) Oral anabolic steroid | 8 | 10 | 0 | C High-risk profile 5.1 |
| 19 | Trenbolone Injectable 19-nor steroid (~5x androgen activity) | 8 | 10 | 0 | C High-risk profile 5.1 |
| 20 | Masteron (drostanolone) Injectable DHT-derivative | 6 | 6.5 | 3.5 | C High-risk profile 5.1 |
| 21 | HIF stabilizers / prolyl-hydroxylase inhibitors (roxadustat / daprodustat / vadadustat) HIF activating agent | 6 | 5 | 3.5 | C High-risk profile 4.9 |
| 22 | MK-677 (ibutamoren) Oral ghrelin receptor agonist | 6 | 5 | 3.5 | C High-risk profile 4.9 |
| 23 | Myostatin / activin-pathway inhibitors (non-bimagrumab) Myostatin/activin blockade | 6 | 5 | 3.5 | C High-risk profile 4.9 |
| 24 | Ipamorelin Selective ghrelin receptor agonist | 3 | 5 | 7 | C 4.9 |
| 25 | Ligandrol (LGD-4033) SARM | 4.5 | 5 | 5 | C 4.8 |
| 26 | Artificial oxygen carriers / blood doping methods Oxygen delivery manipulation | 6 | 8 | 2 | C High-risk profile 4.7 |
| 27 | Cardarine (GW501516) PPAR-delta agonist (not a SARM) | 6 | 10 | 0 | C- High-risk profile 4.2 |
| 28 | HGH (recombinant human growth hormone) Recombinant peptide hormone | 4.5 | 5 | 3.5 | C- High-risk profile 4.2 |
| 29 | CJC-1295 (with/without DAC) GHRH analog | 3 | 5 | 5 | C- 4.1 |
| 30 | GHRP-2 / GHRP-6 Ghrelin receptor agonists (earlier generation) | 3 | 5 | 5 | C- 4.1 |
| 31 | Mesterolone (Proviron) Oral DHT-derivative androgen / TRT adjunct | 3 | 3.5 | 5 | D+ 3.9 |
| 32 | Other GH secretagogues / GHRPs GH secretagogue / ghrelin receptor agonist | 3 | 3.5 | 5 | D+ 3.9 |
| 33 | RAD-140 (testolone) SARM | 3 | 6.5 | 3.5 | D+ High-risk profile 3.7 |
| 34 | Long-acting GH analogs and GH fragments Growth hormone analog / fragment | 3 | 3.5 | 3.5 | D High-risk profile 3.3 |
| 35 | ACP-105 SARM | 2 | 5 | 4 | D 3.3 |
| 36 | LGD-3303 SARM | 2 | 5 | 4 | D 3.3 |
| 37 | Ryanodine stabilizers / fast skeletal muscle troponin activators Muscle contractility modulator | 2.5 | 5 | 3 | D High-risk profile 3.1 |
| 38 | IGF-1 LR3 (long R3 insulin-like growth factor-1) Modified IGF-1 analog | 3 | 5 | 2 | D High-risk profile 2.9 |
| 39 | Veterinary growth promoters (ractopamine / zilpaterol / zeranol) Veterinary beta-agonist / estrogenic growth promoter | 3 | 5 | 2 | D High-risk profile 2.9 |
| 40 | Andarine (S-4) SARM | 2 | 5 | 3 | D High-risk profile 2.9 |
| 41 | S-23 SARM | 2 | 5 | 3 | D High-risk profile 2.9 |
| 42 | YK-11 Myostatin inhibitor / SARM-like | 2 | 5 | 3 | D High-risk profile 2.9 |
| 43 | Gene and cell doping (performance-enhancing) Gene/cell doping method | 2 | 5 | 0 | F High-risk profile 1.7 |
| 44 | Growth-factor doping agents (FGF / HGF / PDGF / VEGF / MGF) Growth factor / tissue-remodeling signal | 2 | 5 | 0 | F High-risk profile 1.7 |
This category has one of the widest gaps between effect size and risk in the database. Resistance training and several supplements combine higher grades with comparatively favourable Safety scores in studied settings. Other compounds have large, well-documented muscle-building effects alongside serious health and legal consequences. The rankings keep those axes visible side by side.
Strong evidence and lower reported risk
Resistance training has the highest composite in this category. Creatine monohydrate is extensively studied, with reliable strength and lean-mass gains and generally favourable safety findings. Adequate protein and, to a lesser degree, beta-alanine and HMB also occupy the evidence-backed, lower-risk portion of the ranking.
Approved and nonmedical contexts
Testosterone replacement has efficacy evidence in hypogonadal men, and the TRAVERSE trial (2023) found no increase in major cardiac events versus placebo in a higher-risk hypogonadal population. Supraphysiological use has a different safety profile and is illegal without a prescription. SARMs such as ostarine produce anabolic effects alongside liver, cardiovascular, and hormone-suppression risks; they are not approved for human use and are banned in sport.
Large effect, large cost
Classic anabolic steroids such as trenbolone and oxymetholone produce large anabolic effects alongside substantial reported harms, reflected in very low Safety scores. GH-secretagogue peptides such as ipamorelin, CJC-1295, and MK-677 raise growth hormone and IGF-1, while human outcome evidence remains thin and much of the supply is gray-market. The safety context label makes those findings visible without replacing the Benefit axis.
Frequently asked
Which muscle interventions combine stronger evidence with favourable safety findings?
Resistance training and adequate protein have broad evidence, while creatine monohydrate is among the most-researched sports supplements and produces reliable strength and lean-mass gains with generally favourable tolerability in studied populations.
What safety findings are reported for SARMs?
No regulator has approved them for human use. SARMs can build muscle but carry liver, cardiovascular, and hormone-suppression risks, are frequently mislabeled on the gray market, and are banned in sport. They score poorly on safety here despite real anabolic effects.
What cardiovascular findings are reported for TRT?
For men with genuine hypogonadism, the TRAVERSE trial (2023) found no increase in major cardiac events versus placebo, which was reassuring. Supraphysiological or non-prescribed use is a different, higher-risk situation and is illegal without a prescription.
Scores reflect the published evidence, not a recommendation to use any compound or protocol. Nothing here is medical advice. How we score →